语言版本

Time of issue:2021-09-02 16:56:33
搜索
Search
All categories

Product name

CAS No.

Specification

Documentation

Acitretin

55079-83-9

EP/USP/in-house

DMF available

Acrivastine

87848-99-5

In-house

DMF available

Adapalene

106685-40-9

In-house

Technical Package available

Alitretinoin

5300-03-8

In-house

DMF available

Amino-polypeptide

107-71-1

In-house

Technical Package available

Anastrozole

120511-73-1

In-house

DMF preparation

Bendamustine HCl

3543-75-7

USP / in-house

DMF available

Benzoyl Peroxide

94-36-0

In-house

Technical Package available

Bepotastine Besilate

190786-44-8

In-house

Technical Package available

Betamethasone Dipropionate

5593-20-4

In-house

Technical Package available

Betamethasone Sodium Phosphate

151-73-5

EP /USP/in-house

Technical Package available

Bexarotene

153559-49-0

In-house

DMF available

Bilastine

202189-78-4

In-house

DMF preparation

Butinafine Hydrochloride

101827-46-7

In-house

Technical Package available

Calcipotriol

112965-21-6;
147657-22-5

EP / USP

DMF available

Calcium Levofolinate

80433-71-2

EP / JP

DMF available

Clobetasone Butyrate

25122-57-0

In-house

DMF preparation

Dapsone

80-08-0

In-house

Technical Package available

Desonide

638-94-8

In-house

Technical Package available

Dutasteride

164656-23-9

In-house

DMF preparation

Econazole Nitrate

24169-02-6

In-house

Technical Package available

Etoposide phosphate

117091-64-2

In-house

Technical Package available

Fluticasone propionate

80474-14-2

In-house

DMF preparation

Halometasone

50629-82-8

In-house

Technical Package available

Hydrocortisone Butyrate

13609-67-1

In-house

Technical Package available

Imiquimod

99011-02-6

In-house

Technical Package available

Isoniazid

54-85-3

In-house

Technical Package available

Isotretinoin

4759-48-2

EP / USP

DMF available

Itraconazole

84625-61-6

In-house

Technical Package available

Laurocapram

59227-89-3

In-house

Technical Package available

Levocetirizine HCl

130018-87-0

USP / in-house

DMF available

Linezolid

165800-03-3

USP / in-house

DMF available

Methoxsalen

298-81-7

In-house

Technical Package available

Methylprednisolone Hemisuccinate

2921-57-5

In-house

Technical Package available

Moxifloxacin HCl

186826-86-8

EP / USP

DMF available

Naftifine HCl

65473-14-5

USP

DMF available

Olopatadine HCl

140462-76-6

USP / JP

DMF preparation

Palonosetron HCl

135729-62-3

USP / in-house

DMF preparation

p-aminosalicylic acid

65-49-6

In-house

Technical Package available

Paricalcitol

131918-61-1

USP / in-house

DMF available

Pasiniazide

2066-89-9

In-house

Technical Package available

Penciclovir

39809-25-1

In-house

Technical Package available

Pyrazinamide

98-96-4

In-house

Technical Package available

Rifabutin

72559-06-9

In-house

Technical Package available

Rifapentine

61379-65-5

In-house

Technical Package available

Rivaroxaban

366789-02-8

In-house

DMF preparation

Roflumilast

162401-32-3

In-house

DMF available

Ruxotinib phosphate

1092939-17-7

EP / USP

DMF preparation

Tadalafil

171596-29-5

In-house

DMF preparation

Tazarotene

118292-40-3

In-house

DMF preparation

Terbinafine hydrochloride

78628-80-5

In-house

DMF preparation

Thymopentin

69558-55-0

In-house

Technical Package available

Tretinoin

302-79-4

EP/USP

DMF available

Valaciclovir hydrochloride

124832-27-5

In-house

Technical Package available

Viaminate

53839-71-7

In-house

Technical Package available

 

Number of views:
1000
Keywords:
FASLODEX is indicated for the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.
Number of views:
1000
Keywords:
treatment
disease
indicated
metastatic
in
for
progression
is
faslodex
Nintedanib esylate is a small molecule tyrosine kinase inhibitor with antifibrotic and anti-inflammatory activities for the treatment of idiopathic pulmonary fibrosis.
Number of views:
1000
Keywords:
small
treatment
for
pulmonary
is
the
with
fibrosis.
kinase
Ruxolitinib phosphate is indicated for the treatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis (PMF) (also known as chronic idiopathic myelofibrosis), post-polycythemia vera myelofibrosis (PPV-MF), orpost-essential thrombocythemia myelofibrosis (PET-MF).
Number of views:
1000
Keywords:
myelofibrosis
known
Bendamustine HCl was originally manufactured in East Germany (former German Democratic Republic) in 1963.
Number of views:
1000
Keywords:
Bendamustine
treatment
Olopatadine HCl was developed by Kyowa Hakko Kirin, and it was first approved by the FOOD and Drug Administration (FDA) of the United States on December 18, 1996,
Number of views:
1000
Keywords:
Olopatadine
Patanol
Previous page
1

RELATED WEBSITES

友情链接

Time of issue:2020-07-27 00:00:00
Online customer service
Customer service hotline
+86-023-67886928 +86-023-67886928
Service time:
8:30 - 17:30
Customer service group:
在线客服

地址版权

Time of issue:2019-05-10 00:00:00

© 2021 Chongqing Huapont Pharmaceutical Co., Ltd. All Rights Reserved.  渝ICP备2021007919号  1渝公网安备50011702500758号  Powered by:www.300.cn

地址版权手机

Time of issue:2019-05-10 00:00:00

© 2021 Chongqing Huapont Pharmaceutical Co., Ltd.

渝ICP备2021007919号  Powered by:www.300.cn

1渝公网安备50011702500758号